Patrick J Heron
CIK 1365617 · last filed 2026-06-17
Patrick J Heron is a corporate insider who has filed 71 SEC Form 4 insider transactions across 16 companies since 2007. The most recent filing, for MIRM, was dated Jun 17, 2026. Across all open-market trades the lifetime net is +$87.6M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $623.0M across reported positions. 23 SEC filings were submitted jointly with James N Topper.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$623.01M
16
71
$87.63M
Filer Profile
PALO ALTO, CA 94301
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MIRM | Director | 464,713 | $98.22 | $45.64M | $20.35M | 19 | 2026-06-17 |
| ARQT | Director | 59,661 | $23.89 | $1.43M | $9.07M | 16 | 2026-06-12 |
| MBX | Director | 3,927,774 | $59.02 | $231.82M | $10.00M | 4 | 2026-06-05 |
| HilleVax, Inc. (HLVX) Delisted | Director | 8,552,536 | $2.09 | $17.87M | $0 | 4 | 2025-06-25 |
| Imago BioSciences, Inc. (IMGO) Delisted | Director | — | $36.01 | — | $0 | 1 | 2021-07-19 |
| PCVX | Director | 2,309,554 | $59.47 | $137.35M | $4.00M | 3 | 2021-06-03 |
| Iterum Therapeutics plc (ITRM) Delisted | Director | 80,411 | $0.03 | $2.4K | $0 | 5 | 2020-07-06 |
| PASG | Director | 148,862 | $5.00 | $744.3K | $9.90M | 2 | 2020-03-03 |
| Entasis Therapeutics Holdings Inc. (ETTX) Delisted | 10%+ Owner | 1,299,953 | $2.19 | $2.85M | $21.30M | 2 | 2020-01-13 |
| ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | 10%+ Owner | 2,571,450 | $64.97 | $167.07M | $8.00M | 1 | 2019-01-22 |
| ANAB | 10%+ Owner | 3,319,224 | $53.87 | $178.81M | $0 | 2 | 2018-05-15 |
| Tobira Therapeutics, Inc. (TBRA) Delisted | Director | 2,668,570 | — | — | $0 | 3 | 2016-01-14 |
| COLL | Director | 1,196,834 | $22.75 | $27.23M | $1.80M | 2 | 2015-09-14 |
| GKOS | 10%+ Owner | — | $167.25 | — | $0 | 1 | 2015-06-30 |
| Cidara Therapeutics, Inc. (CDTX) Delisted | Director | 7,782 | $221.38 | $1.72M | $3.20M | 1 | 2015-04-22 |
| Trubion Pharmaceuticals, Inc (TRBN) Delisted | Director | 0 | — | — | $0 | 4 | 2010-10-28 |
Recent Filings
71 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-17 | MIRM | Grant (A) | — | $0 | EDGAR |
| 2026-06-12 | ARQT | — | — | $0 | EDGAR |
| 2026-06-09 | ARQT | Grant (A) | +5,778 | $0 | EDGAR |
| 2026-06-05 | MBX | Grant (A) | — | $0 | EDGAR |
| 2026-01-27 | MIRM | Mixed | +290,702 | $9.00M | EDGAR |
| 2025-06-25 | HilleVax, Inc. (HLVX) Delisted | Grant (A) | +17,199 | $0 | EDGAR |
| 2025-06-17 | ARQT | Buy (P) | +2,646 | $34.6K | EDGAR |
| 2025-06-16 | ARQT | Grant (A) | +7,609 | $0 | EDGAR |
| 2025-06-06 | ARQT | Buy (P) | +2,268 | $30.2K | EDGAR |
| 2025-06-06 | MBX | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.